Carmen Bartley
A5016139017- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- Viral Infections and Outbreaks Research
- Viral Infections and Vectors
- SARS-CoV-2 detection and testing
- Respiratory viral infections research
- Mosquito-borne diseases and control
- Spine and Intervertebral Disc Pathology
- Musculoskeletal pain and rehabilitation
- Neuroinflammation and Neurodegeneration Mechanisms
- Pain Management and Treatment
- Disaster Response and Management
Texas Biomedical Research Institute
2020-2022
An urgent global quest for effective therapies to prevent and treat coronavirus disease 2019 (COVID-19) is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987 REGN10933) that targets nonoverlapping epitopes on the severe acute respiratory syndrome 2 (SARS-CoV-2) spike protein. In this report, we evaluate in vivo efficacy antibody both rhesus macaques, which may model mild disease, golden hamsters, more disease. demonstrate REGN-COV-2 can...
Summary There are no known cures or vaccines for COVID-19, the defining pandemic of this era. Animal models essential to fast track new interventions and nonhuman primate (NHP) other infectious diseases have proven extremely valuable. Here we compare SARS-CoV-2 infection in three species experimentally infected NHPs (rhesus macaques, baboons, marmosets). During first 3 days, macaques developed clinical signatures viral systemic inflammation, coupled with early evidence replication...
Abstract An urgent global quest for effective therapies to prevent and treat COVID-19 disease is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV-2 spike protein. In this report, we evaluate in vivo efficacy antibody both rhesus macaques golden hamsters demonstrate that REGN-COV-2 can greatly reduce virus load lower upper airway decrease induced pathological sequalae when...
Marburg virus (MARV) is a filovirus that can infect humans and nonhuman primates (NHPs), causing severe disease death. Of the filoviruses, Ebola (EBOV) has been primary target for vaccine therapeutic development. However, MARV an average case fatality rate of approximately 50%, infectious dose low, there are currently no approved vaccines or therapies targeted at infection with MARV. The purpose this study was to characterize course in cynomolgus macaques intramuscularly exposed Angola...
The primary objective of this study was to characterize the disease course in cynomolgus macaques exposed Sudan virus (SUDV), determine if infection species is an appropriate model for evaluation filovirus countermeasures under FDA Animal Rule. causes (SVD), with average case fatality rate approximately 50%, and while research ongoing, presently there are no approved SUDV vaccines or therapies. Well characterized animal models crucial further developing evaluating SUDV. Twenty (20) were...
Abstract The primary objective of this study was to characterize the disease course in cynomolgus macaques exposed Sudan virus (SUDV), determine if infection species is an appropriate model for evaluation filovirus countermeasures under FDA Animal Rule. causes (SVD), with average case fatality rate approximately 50%, and while research ongoing, presently there are no approved SUDV vaccines or therapies. Well characterized animal models crucial further developing evaluating SUDV. Twenty (20)...